Metabolic syndrome patient compliance with drug treatment

Metabolic syndrome patient compliance with drug treatment

OBJECTIVES: 1) To evaluate the compliance with drug treatment in patients with metabolic syndrome. 2) To determine association between access to and use of medicines, as well as the level of knowledge of cardiovascular risk factors and compliance. INTRODUCTION: Low compliance has been one of the greatest challenges for the successful treatment of chronic diseases. Although this issue has been widely studied in patients with isolated hypertension, diabetes and dyslipidemia, compliance studies involving patients with these concomitant diseases or with metabolic syndrome diagnosis are scarce. METHODS: This was a cross-sectional study involving patients who have been diagnosed with metabolic syndrome according to the IDF criteria. Patients were being treated in a Health-Medical School Center bound to the Public Brazilian Healthcare System. This study was conducted in two phases. Phase I was characterized by analyzing medical records and Phase II involved interviewing the patients. A variation of the Morisky-Green Test was used to evaluate compliance. Compliance was the dependent variable and the independent variables included access to medicines, the use of medicines and the level of knowledge concerning cardiovascular risk factors. RESULTS: Two hundred and forty-three patients were identified as being eligible for Phase II, and 75 were included in the study. The average level of compliance was 5.44 points (standard deviation of 0.68), on a scale ranging from 1.00 to 6.00 points. There was no statistically meaningful association between independent variables and compliance. The level of patient knowledge of diet and dyslipidemia was considered to be low. CONCLUSIONS: Patients involved in this study exhibited a high level of compliance with drug treatment. Further research is needed to better elucidate the compliance behavior of patients who have been diagnosed with metabolic syndrome.

Saved in:
Bibliographic Details
Main Authors: Lopes,Nilcéia, Zanini,Antonio Carlos, Casella-Filho,Antonio, Chagas,Antonio Carlos Palandri
Format: Digital revista
Language:English
Published: Faculdade de Medicina / USP 2008
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000500002
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1807-59322008000500002
record_format ojs
spelling oai:scielo:S1807-593220080005000022008-10-13Metabolic syndrome patient compliance with drug treatmentLopes,NilcéiaZanini,Antonio CarlosCasella-Filho,AntonioChagas,Antonio Carlos Palandri Adherence Hypertension Diabetes Abdominal obesity Drug utilization OBJECTIVES: 1) To evaluate the compliance with drug treatment in patients with metabolic syndrome. 2) To determine association between access to and use of medicines, as well as the level of knowledge of cardiovascular risk factors and compliance. INTRODUCTION: Low compliance has been one of the greatest challenges for the successful treatment of chronic diseases. Although this issue has been widely studied in patients with isolated hypertension, diabetes and dyslipidemia, compliance studies involving patients with these concomitant diseases or with metabolic syndrome diagnosis are scarce. METHODS: This was a cross-sectional study involving patients who have been diagnosed with metabolic syndrome according to the IDF criteria. Patients were being treated in a Health-Medical School Center bound to the Public Brazilian Healthcare System. This study was conducted in two phases. Phase I was characterized by analyzing medical records and Phase II involved interviewing the patients. A variation of the Morisky-Green Test was used to evaluate compliance. Compliance was the dependent variable and the independent variables included access to medicines, the use of medicines and the level of knowledge concerning cardiovascular risk factors. RESULTS: Two hundred and forty-three patients were identified as being eligible for Phase II, and 75 were included in the study. The average level of compliance was 5.44 points (standard deviation of 0.68), on a scale ranging from 1.00 to 6.00 points. There was no statistically meaningful association between independent variables and compliance. The level of patient knowledge of diet and dyslipidemia was considered to be low. CONCLUSIONS: Patients involved in this study exhibited a high level of compliance with drug treatment. Further research is needed to better elucidate the compliance behavior of patients who have been diagnosed with metabolic syndrome.info:eu-repo/semantics/openAccessFaculdade de Medicina / USPClinics v.63 n.5 20082008-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000500002en10.1590/S1807-59322008000500002
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Lopes,Nilcéia
Zanini,Antonio Carlos
Casella-Filho,Antonio
Chagas,Antonio Carlos Palandri
spellingShingle Lopes,Nilcéia
Zanini,Antonio Carlos
Casella-Filho,Antonio
Chagas,Antonio Carlos Palandri
Metabolic syndrome patient compliance with drug treatment
author_facet Lopes,Nilcéia
Zanini,Antonio Carlos
Casella-Filho,Antonio
Chagas,Antonio Carlos Palandri
author_sort Lopes,Nilcéia
title Metabolic syndrome patient compliance with drug treatment
title_short Metabolic syndrome patient compliance with drug treatment
title_full Metabolic syndrome patient compliance with drug treatment
title_fullStr Metabolic syndrome patient compliance with drug treatment
title_full_unstemmed Metabolic syndrome patient compliance with drug treatment
title_sort metabolic syndrome patient compliance with drug treatment
description OBJECTIVES: 1) To evaluate the compliance with drug treatment in patients with metabolic syndrome. 2) To determine association between access to and use of medicines, as well as the level of knowledge of cardiovascular risk factors and compliance. INTRODUCTION: Low compliance has been one of the greatest challenges for the successful treatment of chronic diseases. Although this issue has been widely studied in patients with isolated hypertension, diabetes and dyslipidemia, compliance studies involving patients with these concomitant diseases or with metabolic syndrome diagnosis are scarce. METHODS: This was a cross-sectional study involving patients who have been diagnosed with metabolic syndrome according to the IDF criteria. Patients were being treated in a Health-Medical School Center bound to the Public Brazilian Healthcare System. This study was conducted in two phases. Phase I was characterized by analyzing medical records and Phase II involved interviewing the patients. A variation of the Morisky-Green Test was used to evaluate compliance. Compliance was the dependent variable and the independent variables included access to medicines, the use of medicines and the level of knowledge concerning cardiovascular risk factors. RESULTS: Two hundred and forty-three patients were identified as being eligible for Phase II, and 75 were included in the study. The average level of compliance was 5.44 points (standard deviation of 0.68), on a scale ranging from 1.00 to 6.00 points. There was no statistically meaningful association between independent variables and compliance. The level of patient knowledge of diet and dyslipidemia was considered to be low. CONCLUSIONS: Patients involved in this study exhibited a high level of compliance with drug treatment. Further research is needed to better elucidate the compliance behavior of patients who have been diagnosed with metabolic syndrome.
publisher Faculdade de Medicina / USP
publishDate 2008
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000500002
work_keys_str_mv AT lopesnilceia metabolicsyndromepatientcompliancewithdrugtreatment
AT zaniniantoniocarlos metabolicsyndromepatientcompliancewithdrugtreatment
AT casellafilhoantonio metabolicsyndromepatientcompliancewithdrugtreatment
AT chagasantoniocarlospalandri metabolicsyndromepatientcompliancewithdrugtreatment
_version_ 1756432026031882240

Similar Items